[
  {
    "ts": null,
    "headline": "Pentair Just Paid Out: Is This Industrial Dividend Built to Last?",
    "summary": "Pentair plc (PNR) delivered its latest quarterly dividend of $0.27 per share on February 6, 2026, marking another milestone in a streak that now spans 50 consecutive years of annual dividend increases. At a current price of $102.08, the water treatment specialist offers a modest yield that reflects its growth-oriented profile rather than income maximization ... Pentair Just Paid Out: Is This Industrial Dividend Built to Last?",
    "url": "https://finnhub.io/api/news?id=710033017c7d51a4e173817ae4782814f36730cd00207bfab00c02da982f1244",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770920750,
      "headline": "Pentair Just Paid Out: Is This Industrial Dividend Built to Last?",
      "id": 139073089,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Pentair plc (PNR) delivered its latest quarterly dividend of $0.27 per share on February 6, 2026, marking another milestone in a streak that now spans 50 consecutive years of annual dividend increases. At a current price of $102.08, the water treatment specialist offers a modest yield that reflects its growth-oriented profile rather than income maximization ... Pentair Just Paid Out: Is This Industrial Dividend Built to Last?",
      "url": "https://finnhub.io/api/news?id=710033017c7d51a4e173817ae4782814f36730cd00207bfab00c02da982f1244"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Labs Just Extended Its Dividend Aristocrat Status: What Comes Next?",
    "summary": "Abbott Laboratories just paid its quarterly dividend of $0.63 per share on February 13, 2026, marking a 6.8% increase from the prior quarterly rate. For income investors evaluating this healthcare giant’s dividend sustainability, the payment arrives amid a complex backdrop: strong operational execution in medical devices offset by product recalls and nutrition segment weakness. With ... Abbott Labs Just Extended Its Dividend Aristocrat Status: What Comes Next?",
    "url": "https://finnhub.io/api/news?id=30a01ebd15d97cf3183b108745a744fc11d119190ed600c21c712aa2c390eb63",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770919457,
      "headline": "Abbott Labs Just Extended Its Dividend Aristocrat Status: What Comes Next?",
      "id": 139073090,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Abbott Laboratories just paid its quarterly dividend of $0.63 per share on February 13, 2026, marking a 6.8% increase from the prior quarterly rate. For income investors evaluating this healthcare giant’s dividend sustainability, the payment arrives amid a complex backdrop: strong operational execution in medical devices offset by product recalls and nutrition segment weakness. With ... Abbott Labs Just Extended Its Dividend Aristocrat Status: What Comes Next?",
      "url": "https://finnhub.io/api/news?id=30a01ebd15d97cf3183b108745a744fc11d119190ed600c21c712aa2c390eb63"
    }
  },
  {
    "ts": null,
    "headline": "BairesDev Named Top Global B2B Service Provider by Clutch",
    "summary": "This recognition driven by client reviews reinforces BairesDev’s satisfaction scores, engineering excellence, and global delivery impact.MOUNTAIN VIEW, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BairesDev®, a leading nearshore software development company, today announced it has been ranked #15 on the 2025 Clutch 1000 List, placing it among the top 1% of B2B service providers worldwide. The recognition is based on verified client reviews, a 4.9 out of 5 Clutch score, and a consistent track record",
    "url": "https://finnhub.io/api/news?id=1e273c92bf61a5c925e6457bcbb67360718eb56173e98dd1c50018a6ec25170c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770901200,
      "headline": "BairesDev Named Top Global B2B Service Provider by Clutch",
      "id": 139055870,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "This recognition driven by client reviews reinforces BairesDev’s satisfaction scores, engineering excellence, and global delivery impact.MOUNTAIN VIEW, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BairesDev®, a leading nearshore software development company, today announced it has been ranked #15 on the 2025 Clutch 1000 List, placing it among the top 1% of B2B service providers worldwide. The recognition is based on verified client reviews, a 4.9 out of 5 Clutch score, and a consistent track record",
      "url": "https://finnhub.io/api/news?id=1e273c92bf61a5c925e6457bcbb67360718eb56173e98dd1c50018a6ec25170c"
    }
  },
  {
    "ts": null,
    "headline": "enGene CEO Talks Detalimogene for Community Urology as LEGEND Study Hits Full Enrollment",
    "summary": "enGene (NASDAQ:ENGN) CEO Ron Cooper said the company’s lead product candidate, detalimogene, is being developed with an eye toward the practical needs of urologists treating high-risk non-muscle invasive bladder cancer (HR-NMIBC), particularly in the community setting where the majority of patients",
    "url": "https://finnhub.io/api/news?id=6b2bc2515d9af63a990c874ace5dc0f1b007f5ce49313f95a19f26d40bd076f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770890556,
      "headline": "enGene CEO Talks Detalimogene for Community Urology as LEGEND Study Hits Full Enrollment",
      "id": 139054549,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "enGene (NASDAQ:ENGN) CEO Ron Cooper said the company’s lead product candidate, detalimogene, is being developed with an eye toward the practical needs of urologists treating high-risk non-muscle invasive bladder cancer (HR-NMIBC), particularly in the community setting where the majority of patients",
      "url": "https://finnhub.io/api/news?id=6b2bc2515d9af63a990c874ace5dc0f1b007f5ce49313f95a19f26d40bd076f4"
    }
  },
  {
    "ts": null,
    "headline": "Johnson And Johnson Cardiac Data Fuels Fresh Look At Valuation Upside",
    "summary": "Johnson & Johnson (NYSE:JNJ) presented pilot-phase data for its OMNYPULSE and VARIPULSE atrial fibrillation platforms at the 31st Annual AF Symposium. The company reported industry first safety and effectiveness outcomes for these pulsed field ablation technologies. The data suggest potential for redefining minimally invasive electrophysiology procedures in cardiac care. For you as an investor, this update sits inside Johnson & Johnson’s broader medical technology push, where cardiac care...",
    "url": "https://finnhub.io/api/news?id=0cb23ed83555696e141d7033da2e2973c587e69001a5dc6f4d8138841fbfbfe6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770862552,
      "headline": "Johnson And Johnson Cardiac Data Fuels Fresh Look At Valuation Upside",
      "id": 139052266,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) presented pilot-phase data for its OMNYPULSE and VARIPULSE atrial fibrillation platforms at the 31st Annual AF Symposium. The company reported industry first safety and effectiveness outcomes for these pulsed field ablation technologies. The data suggest potential for redefining minimally invasive electrophysiology procedures in cardiac care. For you as an investor, this update sits inside Johnson & Johnson’s broader medical technology push, where cardiac care...",
      "url": "https://finnhub.io/api/news?id=0cb23ed83555696e141d7033da2e2973c587e69001a5dc6f4d8138841fbfbfe6"
    }
  }
]